Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Ads Therapeutics LLC has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 actions are distributed across 2 distinct art units, which indicates that the technical subject matter is reviewed by two separate specialized groups. The company is working with 3 distinct examiners, resulting in a match between the count of examiners and pending office actions.
The busiest examiner for the portfolio is REILLY, SOPHIA JANE, who is responsible for 1 pending office action. This 1 action represents a portion of the 3 total pending office actions for the company. Because there are 3 distinct examiners for 3 actions, the applicant must navigate 3 different sets of examiner preferences. The 2 distinct art units suggest that at least 2 of the 3 distinct examiners are working within the same art unit or that the 3 actions are split between the 2 units. Practitioners should coordinate strategies to ensure consistency across the 2 art units involved.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REILLY, SOPHIA JANE | 1 | 60.8% | +49.2% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.3% |
| FAY, ZOHREH ALEMZADEH | 1 | 52.2% | -6.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18729941 | ESTERS OF 8-METHYL-8-AZABICYCLO[3.2.1] OCTAN-3-YL 3-HYDROXY-2-PHENYLPROPANOATE | REILLY, SOPHIA JANE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18029323 | TOPICAL OPHTHALMOLOGICAL COMPOSITIONS | CHANDRAKUMAR, NIZAL S | 5d overdue |
| 18729941 | ESTERS OF 8-METHYL-8-AZABICYCLO[3.2.1] OCTAN-3-YL 3-HYDROXY-2-PHENYLPROPANOATE | REILLY, SOPHIA JANE | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18729941 | ESTERS OF 8-METHYL-8-AZABICYCLO[3.2.1] OCTAN-3-YL 3-HYDROXY-2-PHENYLPROPANOATE | REILLY, SOPHIA JANE | — | §102§103§112 | Non-Final OA | — | Pending | Jul 18, 2024 |
| 18029323 | TOPICAL OPHTHALMOLOGICAL COMPOSITIONS | CHANDRAKUMAR, NIZAL S | 1625 | §103Other | Final Rejection | 5d overdue | Pending | Mar 29, 2023 |
| 17927796 | TOPICAL OPHTHALMOLOGICAL COMPOSITIONS AND METHODS FOR TREATING ABNORMAL ANGIOGENESIS | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Final Rejection | 27d | Pending | Nov 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial